Cwm LLC Increases Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

CWM LLC increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 471.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,722 shares of the company's stock after purchasing an additional 19,571 shares during the quarter. CWM LLC's holdings in Apellis Pharmaceuticals were worth $684,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Apellis Pharmaceuticals by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company's stock valued at $572,003,000 after purchasing an additional 85,701 shares during the period. Future Financial Wealth Managment LLC acquired a new position in shares of Apellis Pharmaceuticals during the first quarter valued at approximately $29,000. Hennion & Walsh Asset Management Inc. lifted its position in shares of Apellis Pharmaceuticals by 14.4% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 14,068 shares of the company's stock valued at $827,000 after acquiring an additional 1,766 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Apellis Pharmaceuticals by 94.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 115,453 shares of the company's stock valued at $6,786,000 after acquiring an additional 56,178 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Apellis Pharmaceuticals by 254.5% in the first quarter. Principal Financial Group Inc. now owns 84,604 shares of the company's stock worth $4,973,000 after acquiring an additional 60,741 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company's stock.

Apellis Pharmaceuticals Trading Up 0.3 %

APLS traded up $0.08 on Friday, hitting $28.00. The company had a trading volume of 1,508,172 shares, compared to its average volume of 1,657,443. The company's fifty day moving average price is $34.16 and its 200 day moving average price is $39.51. Apellis Pharmaceuticals, Inc. has a 1 year low of $26.28 and a 1 year high of $73.80. The company has a current ratio of 5.08, a quick ratio of 4.18 and a debt-to-equity ratio of 1.73. The firm has a market cap of $3.40 billion, a P/E ratio of -8.09 and a beta of 0.87.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.03. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The business had revenue of $199.70 million for the quarter, compared to the consensus estimate of $190.89 million. During the same period in the previous year, the firm earned ($1.02) EPS. The business's revenue was up 110.2% on a year-over-year basis. As a group, equities analysts expect that Apellis Pharmaceuticals, Inc. will post -1.37 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on APLS. Mizuho decreased their price objective on Apellis Pharmaceuticals from $42.00 to $39.00 and set a "neutral" rating on the stock in a report on Friday, September 20th. HC Wainwright lowered their price target on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a "buy" rating on the stock in a research report on Friday, August 2nd. Robert W. Baird cut their price objective on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an "outperform" rating for the company in a report on Monday, September 23rd. The Goldman Sachs Group boosted their target price on Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a "buy" rating in a report on Friday, August 9th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a $80.00 price target on shares of Apellis Pharmaceuticals in a report on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Apellis Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $68.00.

Insiders Place Their Bets

In other news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares of the company's stock, valued at approximately $3,623,000. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.80% of the stock is owned by insiders.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).